The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Alfie, from Newry, County Down, was diagnosed with Duchenne muscular dystrophy (DMD) when he was four years old. His dad Jamie Pentony said the new drug, Givinostat, could slow hi ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...